Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 7/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21355515 | 0.90 | RAB9A (0.67) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL17226839 | 0.85 | MMP9 (0.47) | ALOX15RAB9AKDM4ENPC1LMNA | |
| SCHEMBL15642755 | 0.83 | RAB9A (0.61) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL23732403 | 0.82 | RAB9A (0.60) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL30140652 | 0.82 | RAB9A (0.60) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL5623372 | 0.80 | KDM4E (0.78) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL31423089 | 0.79 | MAOB (0.51) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL4907791 | 0.79 | ALOX15 (0.72) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL17368519 | 0.79 | ALOX15 (0.72) | ALOX15RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL71101 | 0.79 | ALOX15 (0.72) | ALOX15RAB9AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALOX15 1564/4885RAB9A 3451/4885KDM4E 738/4885 |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALOX15 1564/4885RAB9A 3451/4885KDM4E 738/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALOX15 1564/4885RAB9A 3451/4885KDM4E 738/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALOX15 1564/4885RAB9A 3451/4885KDM4E 738/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALOX15 1564/4885RAB9A 3451/4885KDM4E 738/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALOX15 1564/4885RAB9A 3451/4885KDM4E 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.